Information for Reviewers of Reviews

MISSION: Science Translational Medicine seeks to promote human health by facilitating communication and cooperation among those dedicated to basic, translational, and clinical research and its application. Published papers should present new data or ideas that significantly advance the application of basic research results to clinical medicine or otherwise contribute to the improvement of human health.

CRITERIA FOR JUDGMENT

Reviews should provide a balanced overview of current knowledge about a disease or health condition or should be a new synthesis of an active area of translational research. For Reviews discussing diseases, the authors should clearly identify bottlenecks in the translational system that are preventing progress in combating the disease. Ideally, Reviews should be comprehensive (but not specialized), interdisciplinary, and provocative. They should be rooted in a balanced survey of the literature.

Overall Recommendation: On the basis of the mission statement above, recommend in your review whether the paper should be published in Science Translational Medicine and provide a detailed critique covering:

1. Significance. Please evaluate how well the Review describes the state of knowledge for the disease or research area and whether it clearly identifies bottlenecks in disease prevention, cure, or treatment. For Reviews that synthesize a current research area, evaluate how well it provides the reader with a balanced, up-to-date overview.

2. Technical Merit. The data cited or presented and the arguments made should justify the conclusions and inferences. The Review should correctly cite important discoveries in the field and should be set in the context of, and acknowledge, work done by others, whether or not they have conflicting views.

3. Comprehensibility. The Review should be written in a broadly accessible style. Readers from other areas of translational medicine should be able to learn from the article what has been firmly established and what are significant unresolved questions and obstacles to progress.

Length. Reviews should be 8,000 words or shorter (including references and notes and legends), with the precise length dictated by the requirements of the topic. There should be about 6 display items (figures and tables).

Supplementary Material. Supplementary material can include methods, text, data, audio, video, or other files that are of interest to the reader and necessary for the integrity and excellence of the paper. It must be directly related to the conclusions of the paper.

Conflict of Interest: If you cannot judge this paper impartially, please notify us immediately. If you have any financial or professional affiliations that may be perceived as a conflict of interest in reviewing the manuscript, describe these as indicated on our online review form.

Confidentiality: We expect reviewers to protect the confidentiality of the manuscript and ensure that it is not disseminated or exploited. Please destroy your copy of the manuscript when you are done. Only discuss the paper with a colleague with permission from the editor. We do not disclose the identity of our reviewers.

Security: We ask reviewers to inform us if they have concerns that release of this paper may pose a danger to public health, safety, or security. Such concerns will be brought to the attention of the Chief Scientific Advisor for further evaluation.

Returning your review: Please return your review through our Science Journals Manuscript Submission and Information Portal at https://cts.sciencemag.org. Log into your Science Journals account to access the paper and the review form. If necessary, we can also receive reviews by e-mail at scitranslmed-review@aaas.org.

Final selection is based on relative quality of papers rather than absolute merit and is constrained by available space in Science Translational Medicine and our commitment to balance subject matter.